Shares of embattled drugmaker Valeant Pharmaceuticals (NYSE: VRX) are pulling an about-face after initially moving higher following the release of its second-quarter earnings results before the opening bell on Tuesday, August 8. While …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock jumps after the company sold Dendreon for hefty gains. Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) jumped more than 14% in pre-market trading yesterday, after the …
Valeant Pharmaceuticals' (VRX) plunging stock price and its accounting problems may have captured the brief attention of America's workers. But the drugmaker's woes could hit some harder than they realize: in their retirement funds. Dozens …
Shares of Valeant Pharmaceuticals crashed Tuesday after the embattled drugmaker failed to reassure investors that it's getting back on track and even conceded for the first time that it's technically in danger of defaulting on its debt. The …
Read closely, because we don't get to say this all too often: Valeant Pharmaceuticals' (NYSE: VRX) stock had a great day on Thursday. The embattled drugmaker, known for growing by acquisition, had lost 95% of its market value since …
Diane Alter: The Valeant Pharmaceuticals Intl. Inc. (NYSE:VRX) stock price is now under attack from iconic investor Charlie Munger. The Valeant stock price has plummeted more than 60% since peaking at $263.81 in August. …
Shareholders, as the chart below indicates, took a cue from Berkshire and began purchasing DaVita stock hand over fist in the autumn ... much higher-profile …
Allergan is the company that makes Botox. The offer that Valeant made is a mixture of cash and stock, hoping to entice the shareholders to vote to allow Valeant to acquire enough Allergan stock to own the company. Allergan has a clause …
Valeant, which has been a favorite stock of hedge-fund moguls Bill Ackman, John Paulson and Jeff Ubben, fell almost 17 percent, to close at $166.50 — a loss of more than $33 per share in one day. “Valeant is using precisely the same …